Journal article
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and the Cancer Genome Atlas
SE Johnatty, J Beesley, B Gao, X Chen, Y Lu, MH Law, MJ Henderson, AJ Russell, EL Hedditch, C Emmanuel, S Fereday, PM Webb, EL Goode, RA Vierkant, BL Fridley, JM Cunningham, PA Fasching, MW Beckmann, AB Ekici, E Hogdall Show all
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2013
Abstract
Objective. ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance.We comprehensively evaluated this gene and flanking regions for an associationwith clinical outcome in epithelial ovarian cancer (EOC). Methods. The best candidates from fine-mapping analysis of 21 ABCB1 SNPs tagging C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642) were analysed in 4616 European invasive EOC patients from thirteen Ovarian Cancer Association Consortium(OCAC) studies and The Cancer Genome Atlas (TCGA). Additionally we analysed 1,562 imputed SNPs around ABCB1 in patients receiving cytoreductive surgery and either 'standard' first-line paclit..
View full abstractGrants
Awarded by Breast Cancer Research Foundation
Funding Acknowledgements
[ "Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (No. 1 U19 CA 148537 the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Kamen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.", "The AOCS was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the National Health and Medical Research Council (NHMRC) of Australia (400413, 400281), Cancer Council Victoria, Cancer Council Queensland, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, and Cancer Council Tasmania. G. Chenevix-Trench is a Senior Principal Research fellow of the NHMRC, and this work was supported by NHMRC and Cancer Australia funding. Y. Li is funded by NHMRC grant 496675, and S. MacGregor is supported by an NHMRC career development award, B Gaa was supported by an NHMRC Scholarship and a Cancer Institute NSW Research Scholar Award.", "The Mayo Clinic study (MAY) was supported by R01 CA122443, P50 CA136393.", "SCOTROC biological studies were supported by Cancer Research UK (grant C536/A6689).", "The LAX study (Women's Cancer Program) was supported by the American Cancer Society Early Detection Professorship (120950-SIOP-06-258-06-COUN) and Entertainment Industry Foundation.", "The HAW study was supported by grant R01-CA58598 from the US National Institutes of Health.", "The NEC study was supported by grant R01-CA54419 from the US National Institutes of Health and W81XWH-10-0280 from the Department of Defense.", "The Danish Malignant Ovarian Tumor Study (MAL) was supported by a Danish Cancer Society research grant (94 222 52) and by the Mermaid I project" ]